Furthermore, FOXO4-DRI targets the tumor suppressor p53, a crucial protein, which may lead to various side effects in clinical trials 37
These included CT-996, a once-daily oral small-molecule oral GLP-1 receptor agonist, in Phase I, for treating obesity in patients with and without Type 2 diabetes, as well as two injectable clinical drug candidates: CT-388, a once-weekly subcutaneous injectable in Phase II, for treating obesity in patients with and without Type 2 diabetes, and CT-868, a once-daily subcutaneous injectable, in Phase II, for treating Type 1 diabetes patients with overweight or obesity
Your medical provider can assess your needs using lab tests, track your progress, change your dosing, if necessary, and help with issues that arise
Pharma-One provides high-purity compounds for lab research only, with clear MHRA-compliant wording and fast UK fulfilment